News | June 05, 2014

Cook Medical Begins Studies on Inferior Vena Cava Filters

Cook Medical SCAI CIVIC PRESERVE Clincal Studies Vena Cava Filter

June 5, 2014 — Cook Medical is engaged in two clinical studies that will provide additional data on the safety and effectiveness of inferior vena cava (IVC) filters.

The first study, the Cook Inferior Vena Cava Filter (CIVC) study, will add to Cook’s existing clinical data on its commercially available IVC filters. This includes three previous studies including more than 1,300 patients treated with Cook IVC filters. CIVC will also address filter safety concerns expressed in the 2010 and 2014 safety communications from the U.S. Food and Drug Administration (FDA). The study’s primary endpoints will be technical placement success and one-year freedom from new symptomatic pulmonary embolism, and one-year freedom from major adverse events.

CIVC will collect additional safety and effectiveness data on Cook’s permanent and retrievable filters. Enrollment in the CIVC study began in March 2014. Up to 470 patients at up to 40 international sites will be enrolled in the study.

The second study, the PRESERVE study, will involve collaboration between Cook, the Society for Vascular Surgery, the Society of Interventional Radiology, the FDA and other filter manufacturers, and will enroll patients in the United States only.

“Cook believes in providing physicians the data they need to make the best decisions possible when treating patients. In this case, these two studies should go a long way toward adding to the medical science on IVC filters,” said Mark Breedlove, vice president and global business unit leader for Cook Medical’s Peripheral Intervention clinical division.

For more information: www.cookmedical.com


Related Content

News | Embolic Protection Devices

April 25, 2023 — FastWave Medical, a privately-held company founded by Big Sky Biomedical partners, announces the ...

Home April 25, 2023
Home
News | Embolic Protection Devices

January 11, 2023 — In recent years, transcatheter mitral valve replacement (TMVR) treatment and technology has evolved ...

Home January 11, 2023
Home
News | Embolic Protection Devices

September 17, 2022 — Boston Scientific Corporation has announced results from the PROTECTED TAVR clinical trial ...

Home September 17, 2022
Home
News | Embolic Protection Devices

February 9, 2021 — InspireMD Inc., developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke ...

Home February 09, 2021
Home
News | Embolic Protection Devices

August 6, 2019 — Cardiovascular Systems Inc. (CSI) has acquired the Wirion Embolic Protection System and related assets ...

Home August 06, 2019
Home
News | Embolic Protection Devices

July 19, 2019 — Medical device startup company Filterlex Medical recently completed a series A financing round, raising ...

Home July 19, 2019
Home
News | Embolic Protection Devices

August 3, 2018 — Boston Scientific Corp. announced it has recently closed its acquisition of Claret Medical Inc., a ...

Home August 03, 2018
Home
News | Embolic Protection Devices

July 20, 2018 — Boston Scientific Corp. today has signed an agreement to acquire Claret Medical Inc., which has ...

Home July 20, 2018
Home
News | Embolic Protection Devices

June 7, 2018 — The first clinical cases have been completed where the Emboliner Embolic Protection Catheter was used ...

Home June 07, 2018
Home
News | Embolic Protection Devices

May 8, 2018 — One-year results from the Sentinel Cerebral Protection System show it can reduce the incidence of stroke ...

Home May 08, 2018
Home
Subscribe Now